A randomized, double-blind pilot study of Yin-Chen-Hao-Tang in treating obese people with fatty liver

For obese people with fatty liver, dose Yin-Chen-Hao-Tang has effect on fatty liver degree?

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612001288819

Enrollment

Registered

2012-12-12

Start date

2011-04-11

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Yin-Chen-Hao-Tang is a traditional Chinese herbal remedy that has efficacy in treating jaundice in past study. In this study, we want to see if Yin-Chen-Hao-Tang can improve degree of fatty liver in obesity. Capsule with extract granule of Yin-Chen-Hao-Tang is used in treating group for 8 weeks, placebo with 1/100 amount of Yin-Chen-Hao-Tang capsule is used in controlled group. The degree of fatty liver is assessed by ultrasonography before and after treatment. Liver function and blood lipid level are also evaluated.

Interventions

Yin-Chen-Hao-Tang is a traditional Chinese herbal remedy composed of Artemisia capillaris (Yin Chen), Gardenia jasminoides Ellis (Zhi Zi) and Rheum officinale Baill (Da Huang). Patients were treated with Yin-Chen-Hao-Tang (extract granule; 0.375 gm/capsule; oral use), 4 capsules per time and 3 times per day , the treating course is 8 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver)

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

participant who is obese with fatty liver that is diagnosed at outpatient department

Exclusion criteria

1.Patient has ALT and AST levels of over 1000 u/L 2.Patient has a-Fetoprotein (AFP) levels of over 2 upper laboratory norms. 3.Patient is pregnant 4.Patients with alcoholic or drug abuse 5.Patients treatment with drugs, e.g. corticosteroids, high-dose estrogens, methotrexate, amiodarone, calcium channel blockers, spironolactone, sulfasalazine, naproxen, or oxacillin. 6.Patient has total cholesterol (TC) and triglyceride (TG) over 300 u/L 7.Patient has fast plasma glucose over 126 mg/dl, and postprandial plasma glucose over 200mg/dl 8.Patient has HBsAg positive 9.Patient has Anti-HCV positive 10.Patient with a malignancy which can influence prognosis 11.Patient has BP less than 90/50 mm/Hg

Outcome results